Press Release

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, November 12th, 2024: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for second quarter of FY2025.

NATCO records ₹1434.9 Crore consolidated revenue and INR 676.5 Crore, profit after tax, for Q2 FY25

NATCO recorded consolidated total revenue of INR 1434.9 Crore for the second quarter of FY2025 that ended on 30th September 2024, as against INR 1060.8 Crore for the same period last year, reflecting a growth of 35.3%. The net profit for the period, on a consolidated basis, was INR 676.5 Crore as against INR 369.0 Crore same period last year, showing robust growth of about 83%.

The company has shown continued strong growth during the second quarter driven by exports formulation business and stable domestic pharma business.

The Board of Directors has declared second interim dividend of INR 1.50 per equity share, for FY 2024-25.

Segmental Revenue Split (INR Cr)

Segment	Q2FY25	Q1FY25	Q2FY24
Active Pharmaceutical Ingredients (API)	49.6	39.2	77.8
Formulations, Domestic	102.3	102.2	102.5
Formulations, Export (Incl. profit share and subs)	1211.3	1210.1	792.3
Other operating and non-operating income	57.6	43.6	32.4
Crop Health Sciences (CHS)	14.1	15.6	55.8
Total	**1434.9**	**1410.7**	**1060.8**

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter)

For further information please contact:

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/investors@natcopharma.co.in

Rajesh Chebiyam, EVP - CHS

rajesh.chebiyam@natcopharma.co.in